772 small residual mediastinal mass on CT after four cycles. At two years of follgw-up, the patient has resumed full professional activity.
Comment
Acknowledgement We are indebted to Prof. H. Biirgi (Biirgerspital Solothurn) for providing clinical data.
A. von Rohr,1 A. Zimmermann,2 K. W. Brunner1 & M.F.Fey 1 Institute of Medical Oncology? InselspitaL, 3010 Bern & Department of Pathology,2 University of Berne, Switzerland
References 1. Grigor KM. The role of histopathology in germ cell tumours: a review. In: Jones WG, Ward AM, Anderson CK (eds): Germ Cell Tumours II. Proc of the 2nd Germ Cell Tumour Conference, 1519 April 1985, Leeds, England. Adv Biosciences 1985; 55: 3743. 2. Pugh RCB, Cameron KM. Teratoma. In: Pugh RCB (ed.): Pathology of the testis. Blackwell, Oxford, 1976, pp. 199-244. 3. Mostofi FK, Sesterhenn IA. Pathology of germ cell tumors of testes. In: Khoury S, Kiiss R, Murphy GP, Chatelain C, Karr JP (eds): Testicular cancer. Alan R. Liss, New York, 1985, pp. 1-34.
Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer LY 186641 (sulofenur) is a novel oral anti-tumor agent which belongs to the sulfonylurea class of hypoglycemic agents. In preclinical testing it demonstrated activity against Lewis lung and Madison lung carcinomas [1], and Phase I clinical trials showed no significant gastrointestinal toxicity, alopecia, or myelosuppression. The dose limiting toxicities observed were hemolytic anemia and reversible methemoglobinemia. The encouraging murine results and the unusual spectrum of toxicity led to our study oral sulofenur in previously untreated patients with extensive small cell lung cancer (SCLC) in the hope that if this agent demonstrated significant activity, it might be incorporated into current chemotherapy protocols at full dose in view of its lack of competing toxicity.
Patients were eligible for study if they had measurable disease, life expectancy >12 weeks, performance status 0 or 1, hemoglobin MOO g/L, neutrophils >1.5 x 109/L, platelets MOO x 109/L, bilirubin
Comment
Acknowledgement We are indebted to Prof. H. Biirgi (Biirgerspital Solothurn) for providing clinical data.
A. von Rohr,1 A. Zimmermann,2 K. W. Brunner1 & M.F.Fey 1 Institute of Medical Oncology? InselspitaL, 3010 Bern & Department of Pathology,2 University of Berne, Switzerland
References 1. Grigor KM. The role of histopathology in germ cell tumours: a review. In: Jones WG, Ward AM, Anderson CK (eds): Germ Cell Tumours II. Proc of the 2nd Germ Cell Tumour Conference, 1519 April 1985, Leeds, England. Adv Biosciences 1985; 55: 3743. 2. Pugh RCB, Cameron KM. Teratoma. In: Pugh RCB (ed.): Pathology of the testis. Blackwell, Oxford, 1976, pp. 199-244. 3. Mostofi FK, Sesterhenn IA. Pathology of germ cell tumors of testes. In: Khoury S, Kiiss R, Murphy GP, Chatelain C, Karr JP (eds): Testicular cancer. Alan R. Liss, New York, 1985, pp. 1-34.
Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer LY 186641 (sulofenur) is a novel oral anti-tumor agent which belongs to the sulfonylurea class of hypoglycemic agents. In preclinical testing it demonstrated activity against Lewis lung and Madison lung carcinomas [1], and Phase I clinical trials showed no significant gastrointestinal toxicity, alopecia, or myelosuppression. The dose limiting toxicities observed were hemolytic anemia and reversible methemoglobinemia. The encouraging murine results and the unusual spectrum of toxicity led to our study oral sulofenur in previously untreated patients with extensive small cell lung cancer (SCLC) in the hope that if this agent demonstrated significant activity, it might be incorporated into current chemotherapy protocols at full dose in view of its lack of competing toxicity.
Patients were eligible for study if they had measurable disease, life expectancy >12 weeks, performance status 0 or 1, hemoglobin MOO g/L, neutrophils >1.5 x 109/L, platelets MOO x 109/L, bilirubin
